We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00097799
First Posted: December 1, 2004
Last Update Posted: November 30, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
November 30, 2004
December 1, 2004
November 30, 2016
 
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
Not Provided
Expanded Access
  • Drug: Tipranavir
    500 mg twice daily
  • Drug: Ritonavir
    200 mg twice daily
Not Provided
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
United States
Puerto Rico
 
NCT00097799
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
October 2013